Press Releases

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

June 3, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 17, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--May 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 6, 2024

– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential ...

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

April 29, 2024

– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial st ...

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 17, 2024

– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mas ...

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 4, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

March 27, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 27, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...

Stoke Therapeutics Announces Proposed Public Offering

March 26, 2024

BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 26, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 25, 2024

– As of December 31, 2023 , Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to f ...

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modif ...

March 25, 2024

– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency ...
Investor Inquiries